Research map: Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling

Back to the article

Papers in this map

  1. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine · Daniel D. Von Hoff · 2013 · 6834 citations · Cited by this paper
  2. Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns · 2026 · Related
  3. Cancer statistics, 2025 · Rebecca L. Siegel · 2025 · 2992 citations · Cited by this paper
  4. Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study · 2026 · Related
  5. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions · Jonathan M. L. Ostrem · 2013 · 2593 citations · Cited by this paper
  6. Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence · 2026 · Related
  7. The PRIDE database at 20 years: 2025 update · Yasset Pérez‐Riverol · 2024 · 2054 citations · Cited by this paper
  8. Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway · 2026 · Related
  9. Pancreatic Cancer · Wungki Park · 2021 · 1938 citations · Cited by this paper
  10. Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapy · 2026 · Related
  11. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function · Paul Säftig · 2009 · 1730 citations · Cited by this paper
  12. Natural Autoantibodies Negatively Correlate with Hepatocellular Carcinoma Incidence in Cirrhosis · 2026 · Related
  13. FAK in cancer: mechanistic findings and clinical applications · Florian J. Sulzmaier · 2014 · 1443 citations · Cited by this paper
  14. BRAF Inhibition–Associated Nuclear Remodeling is Linked to Cancer-Associated Fibroblast Activation · 2026 · Related
  15. Acquired Resistance to KRAS G12C Inhibition in Cancer · Mark M. Awad · 2021 · 1244 citations · Cited by this paper
  16. Tissue Context Shapes Distinct Premalignant Outcomes in an HPV16 E6/E7-Mutant Pik3ca Transgenic Mouse Model · 2026 · Related
  17. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor · Matthew Robert Janes · 2018 · 1203 citations · Cited by this paper
  18. Glioblastoma subtypes exhibit distinct migration mechanics and immune responses · 2026 · Related
  19. Analysis of drug combinations: current methodological landscape · Julie Foucquier · 2015 · 1152 citations · Cited by this paper
  20. Interleukin-34–Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis · 2026 · Related
  21. Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein · Jurre J. Kamphorst · 2015 · 917 citations · Cited by this paper
  22. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State · Matthew P. Patricelli · 2016 · 771 citations · Cited by this paper
  23. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor · Xiaolun Wang · 2021 · 756 citations · Cited by this paper
  24. Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer · James S. Duncan · 2012 · 755 citations · Cited by this paper
  25. Induction of Membrane Ruffling and Fluid-Phase Pinocytosis in Quiescent Fibroblasts by ras Proteins · Dafna Bar‐Sagi · 1986 · 742 citations · Cited by this paper
  26. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism · Piro Lito · 2016 · 703 citations · Cited by this paper
  27. Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer · Jay B. Fell · 2020 · 628 citations · Cited by this paper
  28. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor · Jill F. Hallin · 2022 · 549 citations · Cited by this paper
  29. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation · Noritaka Tanaka · 2021 · 536 citations · Cited by this paper
  30. Diverse alterations associated with resistance to KRAS(G12C) inhibition · Yulei Zhao · 2021 · 474 citations · Cited by this paper
  31. Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells [published erratum appears in J Cell Biol 1990 Mar;110(3):859] · Michele A. West · 1989 · 459 citations · Cited by this paper
  32. Activation of the small GTP-binding proteins rho and rac by growth factor receptors · Catherine D. Nobes · 1995 · 439 citations · Cited by this paper
  33. Activation of Rac1 by a Crk SH3-binding protein, DOCK180 · Etsuko Kiyokawa · 1998 · 431 citations · Cited by this paper
  34. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer · Marilyne Labrie · 2022 · 385 citations · Cited by this paper
  35. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway · Kevin M. Pumiglia · 1997 · 361 citations · Cited by this paper
  36. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy · Matthew T. Holderfield · 2024 · 357 citations · Cited by this paper
  37. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers · Jingjing Jiang · 2024 · 329 citations · Cited by this paper
  38. Phosphoinositide 3‐kinase‐dependent activation of Rac · Heidi C. E. Welch · 2003 · 324 citations · Cited by this paper
  39. Paxillin phosphorylation at Ser273 localizes a GIT1–PIX–PAK complex and regulates adhesion and protrusion dynamics · Anjana Nayal · 2006 · 310 citations · Cited by this paper

Source: OpenAlex (CC0)